Vertigo - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Vertigo - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Vertigo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Vertigo: Overview
Vertigo is a symptom, rather than a condition itself. It's the sensation that you, or the environment around you, is moving or spinning. This feeling may be barely noticeable, or it may be so severe that you find it difficult to keep your balance and do everyday tasks. Attacks of vertigo can develop suddenly and last for a few seconds, or they may last much longer. If you have severe vertigo, your symptoms may be constant and last for several days, making normal life very difficult. Vertigo is commonly caused by a problem with the way balance works in the inner ear, although it can also be caused by problems in certain parts of the brain. Some cases of vertigo improve over time, without treatment. However, some people have repeated episodes for many months, or even years, such as those with Mйni?re's disease. There are specific treatments for some causes of vertigo. A series of simple head movements (known as the Epley manoeuvre) is used to treat BPPV. Medicines, such as prochlorperazine and some antihistamines, can help in the early stages or most cases of vertigo.
'Vertigo - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vertigo pipeline landscape is provided which includes the disease overview and Vertigo treatment guidelines. The assessment part of the report embraces, in depth Vertigo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vertigo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Vertigo report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vertigo Emerging Drugs
Further product details are provided in the report
Vertigo: Therapeutic Assessment
This segment of the report provides insights about the different Vertigo drugs segregated based on following parameters that define the scope of the report, such as:
Vertigo: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vertigo therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vertigo drugs.
Vertigo Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Vertigo - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Vertigo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vertigo: Overview
Vertigo is a symptom, rather than a condition itself. It's the sensation that you, or the environment around you, is moving or spinning. This feeling may be barely noticeable, or it may be so severe that you find it difficult to keep your balance and do everyday tasks. Attacks of vertigo can develop suddenly and last for a few seconds, or they may last much longer. If you have severe vertigo, your symptoms may be constant and last for several days, making normal life very difficult. Vertigo is commonly caused by a problem with the way balance works in the inner ear, although it can also be caused by problems in certain parts of the brain. Some cases of vertigo improve over time, without treatment. However, some people have repeated episodes for many months, or even years, such as those with Mйni?re's disease. There are specific treatments for some causes of vertigo. A series of simple head movements (known as the Epley manoeuvre) is used to treat BPPV. Medicines, such as prochlorperazine and some antihistamines, can help in the early stages or most cases of vertigo.
'Vertigo - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vertigo pipeline landscape is provided which includes the disease overview and Vertigo treatment guidelines. The assessment part of the report embraces, in depth Vertigo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vertigo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vertigo R&D. The therapies under development are focused on novel approaches to treat/improve Vertigo.
This segment of the Vertigo report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vertigo Emerging Drugs
- AM-125: Auris Medical
- Seliforant: Sensorion
Further product details are provided in the report
Vertigo: Therapeutic Assessment
This segment of the report provides insights about the different Vertigo drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Vertigo
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Vertigo: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vertigo therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vertigo drugs.
Vertigo Report Insights
- Vertigo Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vertigo drugs?
- How many Vertigo drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vertigo?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vertigo therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vertigo and their status?
- What are the key designations that have been granted to the emerging drugs?
- Auris Medical
- Sensorion
- Apsen Farmaceutica
- Otonomy
- Sound Pharmaceuticals
- AM-125
- Seliforant
- APSLXR
- OTO-104
- SPI-1005
Introduction
Executive Summary
Vertigo: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vertigo – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vertigo companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vertigo Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
AM-125: Auris Medical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
APSLXR: Apsen Farmaceutica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Vertigo Key Companies
Vertigo Key Products
Vertigo- Unmet Needs
Vertigo- Market Drivers and Barriers
Vertigo- Future Perspectives and Conclusion
Vertigo Analyst Views
Vertigo Key Companies
Appendix
Executive Summary
Vertigo: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vertigo – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vertigo companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vertigo Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
AM-125: Auris Medical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
APSLXR: Apsen Farmaceutica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Vertigo Key Companies
Vertigo Key Products
Vertigo- Unmet Needs
Vertigo- Market Drivers and Barriers
Vertigo- Future Perspectives and Conclusion
Vertigo Analyst Views
Vertigo Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Vertigo
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Vertigo
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Vertigo
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Vertigo
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
